TEST KIT, CORONAVIRU

The contract is for the procurement of 2,000 kits of the QUICKVUE AT-HOME OTC COVID-19 TEST, a rapid antigen detection kit designed for anterior nasal swab sampling in a dipstick format with two-color visual results—blue control line and red test line—delivering results within ten minutes. Each kit is self-contained, requiring no additional equipment, and includes a tube holder, two prefilled tubes, two swabs, and two test strips, enabling a single user to perform two tests spaced 24 to 36 hours apart. The product is identified by NSN 6550-01-697-6662 and sourced from QUIDEL CORP (P/N 20402). Delivery must be completed within 20 days of award FOB destination to Patuxent River, Maryland, with acceptance inspections conducted at the delivery point under FAR 52.246-2. Technical and quality specifications align with the DLA Master List of Technical and Quality Requirements, including RA001 for technical compliance and RQ011 requiring removal of government identification from non-accepted items. Packaging must follow MIL-STD-2073-1E and DLA’s RP001, with marking adhering to Medical Marking Standard No. 1, superseding MIL-STD-129. The contract incorporates strict compliance with federal regulations including the Buy American Act and Berry Amendment, DFARS 252.225-7001, NIST SP 800-171 for cybersecurity, and basic safeguarding of information systems under FAR 52.240-93. Contractors must comply with employment eligibility verification, combating trafficking in persons, and sustainable product requirements—all under Deviation 2026-O0038. Hazardous material identification is mandatory under FAR 52.223-3. All quotations must be submitted through the DLA Internet Bid Board System, and vendors must be registered in SAM, with certified cost or pricing data required under DFARS 252.215-7994. Successful bidders will use the Wide Area WorkFlow system for invoicing, and resulting contracts are rated under DPAS for national defense and emergency preparedness priorities.